Investor enthusiasm for Gradalis Inc.'s autologous vaccine platform, Furin-ANd-GMCSF (FANG), boosted what began as a $10 million or so Series B round to an amount more than twice that much, and the firm will use the $24 million to move the Phase II ovarian cancer therapy along while expanding manufacturing capabilities. Read More
AlphaCore Pharma Inc. has maintained a low profile since its founding in 2007, perhaps befitting for a biotech working in the rare orphan indication of familial LCAT deficiency (FLD). Read More
• Pernix Therapeutics Holdings Inc., of The Woodlands, Texas, said it completed the acquisition of Cypress Pharmaceuticals Inc. and Hawthorn Pharmaceuticals Inc., both of Madison, Miss. Read More
• Astex Pharmaceuticals Inc., of Dublin, Calif., said it started a Phase II study testing SGI-110 in advanced hepatocellular carcinoma (HCC) patients who failed prior treatment with Nexavar (sorafenib, Onyx Pharmaceuticals Inc. and Bayer AG). Read More
• Bristol-Myers Squibb Co., of New York, and Pfizer Inc., of New York, said the FDA approved Eliquis (apixaban) to reduce the risk of stroke and systemic embolism in patients with nanvalvular atrial fibrillation. Read More
